Arlington, VA; Reykjavik, Iceland and Zurich, Switzerland—February 7th, 2019—Kerecis, the company pioneering the use of fish skin in tissue regeneration today received a notice from Swiss health care authorities that the company’s lead product, Kerecis Omega3 Wound, will be reimbursed in Switzerland. To establish sales in Switzerland, the company will acquire the Swiss life-science company Phytoceuticals. The aim of the acquisition is to establish sales in Switzerland and strengthen Kerecis position in Europe in the field of regenerative treatment of tissue and organ damage.

As of March 1, 2019, Swiss doctors will be able to use Kerecis Omega3 Wound for the treatment of hard-to-heal wounds showing no or very little healing progress under an adequate causal/local 4 week therapy. The innovative fish-skin-based skin substitute has demonstrated clinical efficacy and cost-effectiveness when used on such wounds. This approach has now been confirmed by the decision of the Swiss health care authorities.

Regenerative Technologies Based on Fatty Acids

The products of both Kerecis and Phytoceuticals are rich in naturally occurring Omega fatty acids, which offer multiple health benefits and support the regeneration of damaged human tissue.

Kerecis Omega3 is intact fish skin that, when grafted onto damaged human tissue such as a diabetic or burn wounds, recruits the body’s own cells and ultimately is converted into living tissue. The Kerecis products help the body regenerate damaged tissue because of the structure of the fish skin and the presence of Omega3 polyunsaturated fatty acids. Phytoceuticals’ products, 1 PRIMARY WOUND DRESSING and WOUND, contain Omega fatty acids from natural oils. The products support the healing of post-surgical wounds and minor burns with little or no scarring. In some cases, using the Kerecis and Phytoceuticals products sequentially on the same wound leads to excellent results.

“Switzerland is a single payer healthcare system with 8.5 million people and has the second-highest health care budget per capita after the United States. In the past 15 years the number of people with diabetes in Switzerland has doubled,” says G. Fertram Sigurjonsson, CEO of Kerecis. “It is estimated that 50,000 people in Switzerland suffer from diabetic related wounds resulting in approximately 7500 amputations annually. Phytoceuticals has made good initial inroads on the Swiss market by treating diabetic patients with our combined technologies. We have had good results and believe the combination of our technologies and talents will make a stronger global company.”

“We are thrilled by the decision of the Swiss healthcare authorities to now reimburse Kerecis in Switzerland for outpatient care,” says Eduardo Theiler, CEO of Phytoceuticals. “When we introduced Kerecis Omega3 to Swiss doctors, it became clear to us that the product has great potential here in Switzerland and for all of Europe, where tissue damage, including diabetic wounds due to the diabetic epidemic, is on the rise.”

Eduardo Theiler, the CEO of Phytoceuticals, will be responsible for Kerecis' operations in Europe in the integrated company. The acquisition is pending the approval of the shareholders of both companies and is expected to close first quarter 2019.

About Kerecis

Kerecis is pioneering the use of fish skin and fatty-acids in the globally expanding cellular therapy and regenerative medicine market. The fatty-acid rich (including Omega3) products from the company's patented technologies enable the body to regenerate tissues, rather than simply repair them and risk scarring. The Kerecis products, which are based on Omega3 rich fish skin, are currently being used to regenerate tissue in trauma and chronic wounds such as burns and diabetic wounds. Kerecis is also developing products for areas such as oral surgery, plastic surgery and neurological applications. The company‘s mission is to support the body’s ability to regenerate tissues and its vision is to become a world leader in tissue regeneration. For more information, visit www.kerecis.com.

About Phytoceuticals

Phytoceuticals is a life-science company that develops and markets medicinal products from natural product extracts. The company’s current focus is to develop first-in-class fatty-acid-based solutions for major indications in dermatology. The company has established a sales network in Switzerland and several international markets. Phytoceuticals was founded in 2008 in Switzerland by Eduardo Theiler. For more information, visit www.phytoceuticals.ch.

###

Kerecis is a trademark of Kerecis. All other company and product names are trademarks of their respective owners.

Contact

Kay Paumier
Communications Plus
408-370-1243
Cell: 408-866-1177
kay@communicationsplus.net

Posted
AuthorEduardo Theiler

Zurich, December 5, 2018 – Phytoceuticals Ltd., a life science company focusing on the development and marketing of plant-based wound care products, today announced that the Company has received approval from the Australian Therapeutic Goods Administration (TGA) to market 1 PRIMARY WOUND DRESSING® in Australia.

# # # # #

Posted
AuthorEduardo Theiler

We are very happy to announce that as of March 2018, 1 PRIMARY WOUND DRESSING® and WOUND can be used for the treatment of children wounds.

In collaboration with several health care specialists the necessary clinical data have been generated in order to demonstrate the safe and effective use of 1 PRIMARY WOUND DRESSING® and WOUND for the treatment of children wounds. 

After the positive reimbursement decisions for 1 PRIMARY WOUND DRESSING® in Switzerland and UK in 2017 this is another very positive milestone for Phytoceuticals.

For further information, please contact eduardo.theiler@phytoceuticals.ch

 

Posted
AuthorEduardo Theiler

We are very happy to announce that 1 PRIMARY WOUND DRESSING® will be listed in the November 2017 edition of the Drug Tariff.

Not least due to the support from many wound experts the authorities have been convinced that 1 PRIMARY WOUND DRESSING® is a wound care product, which enables a clinically effective, useful and cost effective treatment of acute and chronic wounds. We are very proud to have been able to demonstrate that even in today’s environment, which is dominated by cost savings and increasing regulatory requirements, it is possible to find a path to market and full reimbursement for an innovative product.

Posted
AuthorEduardo Theiler

We are extremely pleased and proud!

8 years ago we started with the development of 1 PRIMARY WOUND DRESSING®  and just now, the Federal Office of Public Health has decided to create a new category on the „Mittel- und Gegenständeliste“ (MiGeL), thereby enabling full reimbursement of 1 PRIMARY WOUND DRESSING® by the compulsory basic insurance. 

As of January 1, 2017, reimbursement for 1 PRIMARY WOUND DRESSING® is granted (MiGeL number 34.70.01.00.1) with a reimbursement amount of CHF 25.00 for 10ml.

The path to full reimbursement was a long, stony way. Not least due to the support from many wound experts the authorities have been convinced that 1 PRIMARY WOUND DRESSING® is a wound care product, which enables a clinically effective, useful and cost effective treatment of acute and chronic wounds. We are very proud to have been able to demonstrate that even in today’s environment, which is dominated by cost savings and increasing regulatory requirements, it is possible to find a path to market and full reimbursement for an innovative product if a great team is engaged with a lot of passion supported by doctors and wound experts.

Posted
AuthorEduardo Theiler

Management of severe head injury with brain exposure in three loggerhead sea turtles

The JOURNAL DISEASES OF AQUATIC ORGANISMS has just published the exciting work of FIORELLA CARNEVALI and her team, treating sea turtle wounds with one PRIMARY WOUND DRESSING:

http://www.int-res.com/abstracts/dao/v119/n2/

one PRIMARY WOUND DRESSING can be used to treat all types of animal wounds and can be ordered online:

www.onewound.com

 

Posted
AuthorEduardo Theiler

DANI ARNOLD supports WUNDE as ambassador

We are very happy to announce that the passionate alpinist DANI ARNOLD supports WUNDE as its new ambassador.

Dani grew up in the "Schächental" in Switzerland on 1720 meters above sea level and works as a mountain guide. He is a very passionate alpinist who at some point in his alpinist life climbed the Eiger North Face, which was followed by climbing some of the most difficult ice and mixed routes of Europe. Dani was also part of the first successful winter ascents of Torre Egger in Patagonia. After additional successes in Alaska and the "Breitwandflue" Trilogy Dani obtained international recognition because of his incredible speed solo ascents of the Eiger North Face, Matterhorn North Face and other, much more difficult routes.

For further information on Dani please visit his website: www.daniarnold.ch

 

For further information:

Eduardo Theiler, eduardo.theiler@phytoceuticals.ch

Posted
AuthorEduardo Theiler

Zurich, September 23, 2015 – Phytoceuticals Ltd., a life science company focusing on the development and marketing of plant-based wound care products, today announced that the Company has received approval from the Korean Food and Drug Administration (KFDA) to market 1 PRIMARY WOUND DRESSING® in South Korea.

To develop the Korean market, Phytoceuticals Ltd. has established a distribution partnership with PUBLICMED, a company specialized in the import and sales of high end wound care products for medical professionals and patients.

Eduardo Theiler, CEO of Phytoceuticals Ltd., comments on this new authorization: “This marketing approval in South Korea is a fantastic milestone and success for our company. We are proud to be able to offer our product in Asia's third largest medical device market.”

“Bringing such a new and effective natural product to the Korean market represents an amazing opportunity for our company. We have an existing sub-distributor network and will quickly promote the use of “1” through our channels and make “1” available to medical professionals and patients”, said Minkoo Jeong, CEO of PUBLICMED.

# # # # #

Posted
AuthorEduardo Theiler

We are very happy to announce that SIMONE NIGGLI-LUDER, winner of 23 Olympic Gold Medals in Orienteering, supports our summer promotion activities in Swiss pharmacies and drug stores as ambassador.

Simone is biologist, mother of 3 children and uses WUNDE for all smaller and bigger "accidents". 

The WUNDE summer promotion includes an extensive POS presence combined with the chance to win an Orienteering training with Simone and is being rolled out this summer in Switzerland.

For more information contact:

Eduardo Theiler, eduardo.theiler@phytoceuticals.ch

 

 

 

 

Posted
AuthorEduardo Theiler

d-inside, the major Swiss magazine for all drug stores just published a background article on WUNDE.

See:

http://issuu.com/sdvbiel/docs/is_4_2015_de/1?e=0/12020793


Posted
AuthorEduardo Theiler

The JOURNAL OF ANIMAL AND VETERINARY SCIENCES has just published the exciting work of FIORELLA CARNEVALI and her team, treating horse wounds with one PRIMARY WOUND DRESSING:

http://www.openscienceonline.com/journal/archive2?journalId=707&paperId=890

one PRIMARY WOUND DRESSING can be used to treat all types of animal wounds and is distributed in Switzerland by PROVET:

http://provet.ch/

Please contact Phytoceuticals if you want to order one PRIMARY WOUND DRESSING from outside Switzerland.

Posted
AuthorEduardo Theiler

PHYTOCEUTICALS AG NAMES NEW SOUTH AFRICAN DISTRIBUTION PARTNERS

 

ZURICH, Switzerland, August 11, 2014  

Phytoceuticals AG announced today that it has named LIGAMED SA, as the Company’s South African distributor for 1 PRIMARY WOUND DRESSING®, a unique plant-based wound dressing for the treatment of acute and chronic wounds.

Phytoceuticals AG also announced today that it has named FLORDIS SA, as the Company's South African distributor for WOUND, a unique plant-based wound dressing for the treatment of small wounds and burns. WOUND will be sold in South Africa under the brand name FIX.

Posted
AuthorEduardo Theiler

June 18, 2013 - Phytoceuticals AG announced today that it has named Endospin Italia Srl, as the Company’s Italian distributor for 1 PRIMARY WOUND DRESSING®, a unique plant-based wound dressing for the treatment of acute and chronic wounds.

Posted
AuthorEduardo Theiler

June 23, 2011 - The 2011 Frost & Sullivan Western Europe New Product Innovation Award in Advanced Wound Management is presented to Phytoceuticals for its 1 PRIMARY WOUND DRESSING® (‘1’). This innovative wound dressing spray is specially formulated from a proprietary combination of Neem oil and St. John’s Wort oil. ‘1’ is an easy-to-use, 100% natural and highly effective treatment for a wide range of wounds, including acute and chronic wounds.

Posted
AuthorEduardo Theiler
CategoriesPress Release